FDA Commissioner Stephen Hahn presided over the most tumultuous era in FDA’s history, one that will be remembered for the agency’s failure to take aggressive actions at the start of the COVID-19 outbreak,...

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...

As James Frates prepares to depart Alkermes after two decades, the neuroscience company has promoted a pair of executives to lead implementation of the company’s “value enhancement plan” unveiled in December in the wake of...

Ribometrix, Genentech partner for RNA-targeting small moleculesRibometrix Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) are partnering to develop small molecules against undisclosed...

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...

With a pipeline heavy on line extensions and its bestseller headed toward a patent cliff, new Ipsen CEO David Loew is doubling down on the mid-cap biopharma’s commitment to external innovation. But...

Merck sold its shares in Moderna at a price at least three times their value at the beginning of 2020, although the biotech’s value has continued to rise since the divestiture’s completion as its COVID-19...

If they withstand withering legal challenges from the biopharmaceutical industry, hospitals and medical groups, and overcome steep logistic obstacles, rules released by the Trump administration Friday...

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...